#### 1 Diversity of *CFTR* variants across ancestries characterized using 454,727 UK 2 biobank whole exome sequences

3

4 Justin E. Ideozu<sup>1</sup>, Mengzhen Liu<sup>2</sup>, Bridget M. Riley-Gillis<sup>2</sup>, Sri R. Paladugu<sup>2</sup>, Fedik Rahimov<sup>2</sup>,

5 Preethi Krishnan<sup>3</sup>, Rakesh Tripathi<sup>3</sup>, Patrick Dorr<sup>3</sup>, Hara Levy<sup>4</sup>, Ashvani Singh<sup>5</sup>, Jeffery F.
6 Waring<sup>1,2</sup>, and Aparna Vasanthakumar<sup>1</sup>.

- 7
- <sup>1</sup>Genomic Medicine, Genomics Research Center, AbbVie, IL.
- 9 <sup>2</sup>Human Genetics, Genomics Research Center, AbbVie, IL.
- <sup>3</sup>Precision Medicine, AbbVie, IL.
- <sup>4</sup>Department of Pediatrics, Division of Pulmonology and Sleep Medicine, University of
   Wisconsin School of Medicine and Public Health, WI.
- <sup>5</sup>Discovery Research, AbbVie, IL.
- 14
- 15 Keywords: CFTR, whole exome sequencing, UK biobank, cystic fibrosis
- 16

#### 17 Abstract

18

19 Limited understanding of the diversity of CFTR variants across ancestries hampers efforts to 20 advance molecular diagnosis of cystic fibrosis (CF). The consequences pose a risk of delayed diagnoses and subsequently worsened health outcomes for patients. Characterizing the 21 22 distribution of CFTR variants across ancestries is, therefore, critical for revolutionizing molecular diagnoses of CF. By interrogating 454,727 UK biobank whole exome Sequences, we 23 24 detected over 4,000 CFTR variants, including novel ancestry-specific variants, across six 25 ancestries. F508del was the most prevalent CF-causing variant found across the ancestries, 26 except in East Asia, where V520F was the most prevalent. Sixteen participants had two CF-27 causing variants, with two diagnosed as CF. We found 154 participants with a CF-causing and 28 varying clinical consequences (VCC) variant. Overall, participants with multiple clinically 29 relevant variants reported indications significantly associated with CF and its pulmonary phenotypes [Bonferroni adjusted p<0.05]. Potentially, participants with classical CF phenotypes 30 may benefit from current CF therapies. 31

32

#### 33 Introduction

34

In cystic fibrosis (CF), pathogenic variants in the cystic fibrosis transmembrane conductance 35 regulator (CFTR) gene results in system-wide debilitating consequences<sup>1</sup>. Current CFTR 36 37 modulator therapies targeting the basic CFTR defects have yielded both short- and long-term clinical benefits, but they are approved only for patients with certain CFTR variants<sup>2,3</sup>. Even 38 39 within these patients, the response to current CFTR modulator therapies can be variable. Recent 40 advances in genetic technologies have led to the discovery of many CF-causing variants among populations of European ancestry. Although these findings have led to a better understanding of 41 42 the disease prevalence, and improved diagnoses<sup>4</sup>, there is limited knowledge about the 43 distribution of ancestry-specific CFTR variants. Characterizing the broad spectrum of pathogenic 44 and non-pathogenic CFTR variants across ancestries holds promise to revolutionize molecular 45 diagnoses of CF and could enable wider access to personalized CFTR modulator therapies.

47 Most studies that have surveyed the diversity of *CFTR* variants have largely focused on studying persons with CF from European populations<sup>5,6</sup>. This is perhaps driven by the fact that CF 48 predominantly affects individuals from European ancestry, and the disease is less frequent in 49 50 people from other ancestries. Survey reports from a diverse US population shows CF affects individuals of European ancestry (1:3000 live birth) relative to people from other ethnicities, 51 including Africans (1:15000), Asians (1:35,000), and Native Americans (1:10,900)<sup>7,8</sup>. Globally, 52 CF is presumed to affect about 100,000 people and F508del accounts for most of the cases<sup>6,9</sup>. 53 54 Recent reports suggest the spectrum of CF-causing variants vary across ancestries and 55 countries<sup>7,10</sup>. CF-causing variants commonly reported in other ethnic groups, include 3120+1G>A (Africans)<sup>10</sup>, p.W1282X (Ashkenazim)<sup>6,11</sup>, and p.G970D (Chinese)<sup>12</sup>. Although 56 57 these studies have shed insights on common CF-causing variants in non-European populations, 58 carrier screening panels do not often capture the dominant CF-causing variants in some 59 ethnicities<sup>13</sup>. Thus, the prevalence of the disease in other ethnicities, and worldwide, are possibly 60 underestimated.

61

62 Diagnosis of CF can be based on the results of a patients' pilocarpine iontophoresis sweat test (sweat chloride  $\geq$  60 mmol/L) and/or molecular genetic testing (positive for up to two CF-63 causing variants)<sup>14</sup>. One of the advantages of molecular genetic testing is that it could detect both 64 symptomatic and pre-symptomatic individuals, including the potential to determine a patients' 65 66 eligibility for current CFTR modulator therapies. A major drawback of solo reliance on symptomatic diagnoses is that often patients are diagnosed when they are already presenting 67 symptoms, and delayed diagnosis negatively impacts the patients' health outcomes<sup>15</sup>. Early 68 69 diagnosis and interventions, particularly with triple CFTR therapy, results in improved clinical outcomes and could profoundly affect the trajectory of CF lung disease<sup>16</sup>. Carriers of rare 70 71 pathogenic variants not included in carrier screening panels are more likely to have delayed 72 diagnosis which poses a risk of increased morbidity. Thus, it has become critical to characterize 73 the broad spectrum of pathogenic CFTR variants across ancestral populations.

74

75 Determining the clinical and functional relevance of *CFTR* variants is such an inundated task that requires critical examination of the variants' impact on an individual's phenotype. This is 76 77 compounded by the clinical heterogeneity often seen in patients with the same *CFTR* genotype. 78 Efforts driven by CFTR1/2 have led to the identification of 2,110 CFTR variants 79 [http://www.genet.sickkids.on.ca]. Of these, 401 are CF-causing while 49 are variants of varying 80 clinical consequences (VCC), according to the latest CFTR2 annotation [https://cftr2.org]. The 81 CFTR1/2 databases have led to an increased understanding of CF diagnoses and prevalence 82 across populations. However, the variants captured from the CFTR1/2 efforts do not necessarily 83 represent the entirety of potential variants that could possibly exist within the CFTR gene across 84 ancestries. Recent annotations from TopMed Whole Genome Sequencing (WGS) efforts that includes diverse populations indicate that the *CFTR* gene is about 250kb with 56,488 variants<sup>17</sup>, 85 which is longer than the often referenced 189kb length<sup>18</sup>. Although the vast majority of these 86 newly detected CFTR variants are intronic [96%], and their clinical relevance unknown, this 87 underscores the continued need to gain a comprehensive understanding of all pathogenic and 88 89 non-pathogenic variants that possibly exists within the CFTR gene, including those from various 90 ancestries.

92 The complexities associated with characterizing the clinical relevance of *CFTR* variants can be 93 subdued by leveraging population databases, such as UK Biobank (UKBB), that hosts both 94 genomics and phenotypic information of individuals. In this study, we characterized the diversity 95 of CFTR variants across six ancestral populations included in the UKBB. We segregated 96 ancestry-specific CFTR variants, including those that are CF-causing from uncharacterized 97 variants. We estimated the age of certain detected CF-causing variants. For participants with two 98 CF-causing variants or a CF-causing variant and a VCC, we performed phenotype analysis to 99 determine the possible impact of pathogenic CF-variants on their health outcomes. Our work 100 provides the foundation for future studies to explore the clinical relevance of the newly detected 101 *CFTR* variants across the described ancestries.

- 102
- 103 Methods104

### 105 Study population and whole exome sequences

106

107 The dataset used for this study is available in the UKBB public repository and was accessed 108 under application 26041. A total of 454,787 UKBB whole exome sequences were interrogated to 109 characterize the diversity of CFTR variants across ancestries. The demographics and characteristics of the UKBB participants has been described elsewhere<sup>19</sup>, but relevant 110 information such as gender, age and spirometry measures were recorded for each participant. 111 Details on the calling and quality control can be found in previous publication<sup>19</sup>. To maximize 112 113 variant discovery, no further filters were applied except the removal of individuals that 114 subsequently withdrew consent (final N = 454.727). Curated disease phenotypes, defined based 115 on participants primary care and hospital in-patient (HESIN) records, were utilized for 116 association tests with pathogenic CFTR genotypes.

117

# 118 Ancestry designation

119

120 For ancestry designation, we opted to use the classification from the PanUKBB working group (https://pan-dev.ukbb.broadinstitute.org/) which derives the ancestry classification from two 121 large reference datasets, 1000 Genomes Project and Human Genome Diversity Project. Using 122 123 this classification, the participants were grouped into six major groups: African (AFR), American/American Admixed (AMR), Central South Asia (CSA), East Asian (EAS), European 124 125 (EUR), and Middle East (MID). Individuals that did not fall neatly into the large continental 126 classifications were classified as MIX. While this classification limits the full extent of genomic 127 diversity in the UKBB, it permitted an estimation of variant frequencies to other populations. 128 Individuals assigned to the MIX group were included in all other counts and analysis.

129

# 130 Variant annotation

131

Clinically relevant variants (CF-causing and VCCs) detected across the ancestries were classified
 using CFTR2 annotation. CF-causing variants without an assigned Reference SNP cluster ID

134 (rsID) were excluded since they comprised mostly of large indels and structural variants, which

- are often challenging to be called by variant calling tools. Functionally relevant variants (high
- impact variants) were annotated with Variant Effect Predictor<sup>20</sup> and SnpEFF<sup>21</sup> and those high
- 137 impact variants not known to cause CF were recorded. The canonical transcript of CFTR

(ENST00000003084) was used as reference for both tools. CF is an autosomal recessive disease and molecular diagnosis could be based on the possession of two or more clinically relevant variants. Thus, participants with two CF-causing variants, a CF-causing variant and a VCC, and a CF-Causing variant and a non-CF-causing high impact variant, were characterized and prioritized for further association test. Participants with two CF-causing variants were then assigned likely disease severity status (pancreatic sufficient or insufficient) based on their *CFTR* genotype as previously described<sup>22,23</sup>.

145

#### 146 Statistical association analysis

147

148 We categorized participants with certain clinical or functionally relevant variant combinations 149 into three groups: two CF-causing variants, a CF-causing variant and a VCC, a CF-causing 150 variant and a variant of high impact. We tested each of the groups for association with disease 151 phenotypes using Fisher-Exact tests. As pulmonary measures such as forced expiratory volume 152 (FEV) and forced vital capacity (FVC) could reflect pulmonary phenotype, we tested for 153 differences in these measures between participants with two CF-causing variants and the general 154 population. Only associations meeting a Bonferroni corrected adjusted p-value < 5% were 155 considered as statistically significant.

156

### 157 Genealogical estimation of CF-causing variants age

158

To estimate the age of CF-causing variants, we used data from the Atlas of Variant Age (AVA) (<u>https://human.genome.dating/</u>). Models using data from the 1000 Genomes Project (TGP) and the Simons Genome Diversity Project (SGDP), implemented in the Genealogical Estimation of Variant Age (GEVA) tool<sup>24</sup>, were deployed. For variant age estimations, joint mutational and recombinational clocks were considered using an average generation time of 25 years. Estimated age of variants within the *CFTR* gene locus (Chr7: 117,095,837 – 117,366,025) were then reported.

- 166
- 167 **Result**
- 168

# 169 **Over 4000** *CFTR* variants identified across ancestries.

170

171 We interrogated 454,787 whole exome sequences available in the UKBB to characterize the 172 diversity of CFTR variants across six ancestries [AFR, CSA, EAS, EUR, AMR, and MID] and 173 an uncharacterized group (MIX). The median age across all ancestries was greater than 60 years. 174 Except for CSA and MID where over half of the characterized participants were males, most of 175 the ancestries were dominated by females (Table 1). Overall, we detected 4,193 variants across all ancestries in the UKBB, with V470M emerging as the most common variant (Table S1). The 176 177 CFTR variants represented a diverse range of variant types, but over 50% were intronic (Fig. 1) 178 The highest number of *CFTR* variants were detected in Europeans [n=3,192] while the AMR 179 group had the least number of CFTR variants [n=151]. Across the remaining ancestries [CSA, 180 AFR, EAS, and MID], the number of CFTR variants detected [471, 417, 266, and 222 181 respectively] were also much lower when compared to those detected in Europeans (Table 1). 182 Many of the variants detected in this study have never been reported as variants in CFTR. Next, 183 we explored if there were CFTR variants uniquely represented across the ancestries.

184 Interestingly, we found several *CFTR* variants that tend to be ancestry specific (Fig. 2, Table S2). 185 The highest number of unique CFTR variants [2212/3192] was found in Europeans, while the 186 Hispanic/Admixed American group had the least number of unique CFTR variants [23/151]. 187 About 8.3% [37850/454,727] of the overall study population did not fall under a specific 188 ancestry and were categorized as the Mixed group (MIX). The median (interquartile range [IQR] 189 age for the MIX population was 67 (60, 67), with males accounting for 43% of the population. 190 Within the MIX group, we detected a total of 1333 CFTR variants and 28.6% of these variants 191 [n=381] were uniquely found in their population (Table 1).

192

#### 193 **CF-causing variants across ancestries**

194 195 We explored the global distribution of CF-causing variants, variants of varying clinical 196 consequences (VCC), and high impact variants. As shown in Table 2, we found varying 197 distribution of CF-causing (Table S3) and VCC (Table S4) variants across the ancestries. The 198 highest number of CF-causing variants were detected in the EUR population [116/154]. These 199 variants accounted for 75% of all CF-causing variants with RSIDs captured in the study. Nearly 200 50% of the CF-causing variants were found in the MIX population, but lower proportions 201 (<15%) were reported across the other specific ancestries. The AMR group with the least number 202 of detected CFTR variants [151/4193] also had the least number [7/154] of the CF-causing 203 variants (Table 2). F508del was the most prevalent CF-causing variant observed in all ancestries, 204 except in EAS where V520F was the most prevalent (Fig. 3). While F508del represented ~90% 205 of the CF-causing variants found in Europeans, our findings indicate its prevalence was not as 206 high in other ancestries. We further explored whether there were any CF-causing variants that 207 were potentially ancestry-specific. As shown in Figure 4, all ancestries had unique CF-causing 208 variants, but EUR possessed the highest number [n=50] of ancestry-specific CF-causing variants 209 while four groups (AMR, CSA, EAS, and MID) had only one ancestry-specific variant each 210 (Table S5). We also detected VCC variants in all ancestries [Table S4]. The number of VCC 211 variants detected were smaller than the number of CF-causing variants detected across the 212 ancestries, except for AMR and MID populations. R74W was one of the most common variants 213 detected across the ancestries. Except for EUR, R74W featured among the top 5 most common 214 VCC reported in all ancestries. Other VCCs that made the common list included R117H, 215 D1270N, and L967S (Table S6). Interestingly, we found several high impact variants that are not 216 known to be CF-causing or clinically relevant in each ancestry. The highest number of these 217 variants [150/200] were detected in the EUR population. Overall, high impact variants accounted 218 for only a small fraction of the total number of variants reported in each ancestry [ $\leq$  5%] (Table 219 S7) and many of these [127/200] are uncharacterized in CF (Table S8).

220

#### 221 More than one CF-causing variants detected in participants

222

223 With CF being an autosomal recessive disease, we explored the prevalence of participants with 224 two CF-causing variants and those heterozygous for a CF-causing variant and a VCC or high 225 impact variant. We found 16 UKBB participants possessing at least two CF-causing variants 226 (Table 3). These participants were found exclusively in the CSA [n=1], EUR (n=9), and MIX 227 [n=6] populations. The CSA participant was homozygous for V456A, but various CF-causing 228 variant combinations were found in the EUR and MIX populations. F508del was the most

229 common CF-causing INDEL detected across the populations. Interestingly, the two individuals

230 homozygous for F508del were also diagnosed as having CF in UKBB. Many of the participants 231 with two CF-causing CFTR variants had combinations associated with pancreatic sufficiency 232 (96%). The three variant combinations associated with pancreatic insufficiency were 233 R851X/F508del and F508del/F508del [n=2] (Table 3). We found 155 participants that harbored 234 a CF-causing variant and a VCC (Table 4). These participants were found only in the EUR 235 [n=145] and MIX [n=10] populations. R117H was the most reported VCC [49/154] variant in 236 this subset of participants, and its combination with F508del was the most common found in the 237 EUR [38/145] and MIX [5/10] populations. L967S also featured as a common VCC variant. Its 238 combination with F508del was exclusively reported in the EUR population and dominated as the 239 second most common combination (Table 4). Since high impact variants are potentially 240 functionally relevant, we assessed their distribution across the ancestries. Among the 200 high 241 impact variants detected in the participants, the highest number was found in EUR population 242 [150/200] while the least number of these variants [4/200] were reported in both the AMR and 243 EAS populations [Table S7]. We also found a high number of participants heterozygous for a 244 CF-causing and high impact variant [Table S9]. These findings warranted us to interrogate the 245 association of these variant with participants health outcomes.

246

# Classical CF phenotypes reported in participants with two CF-causing variants and VCCs 248

249 Phenotype analysis performed using hospital in-patient records indicated that most of the 250 participants with at least two CF-causing variants presented classical CF phenotypes. Eight 251 (International Classification of Diseases 10<sup>th</sup> Revision (ICD-10) codes were significantly 252 [FDR<0.05] enriched in participants with two CF-causing variants (Fig. 5A). Specifically, ICD 253 codes directly associated with CF [E840, 848, and 849] and colonization with Pseudomonas 254 aeruginosa [B965] were among the top significantly enriched terms. Interestingly, ICD Code 255 U837 which corresponds to Resistance to Multiple Antibiotics also featured among the top 10 256 enriched phenotypes. Although bronchiectasis, a classical consequence of dysfunctional CFTR, 257 was listed among the top, it did not meet our significance threshold when corrected for multiple 258 testing (Fig. 4). With VCC variants resulting in variable clinical outcomes when combined with 259 another CF-causing variant but not often diagnosed as CF, we assessed the phenotypes of 260 participants that fall within this category. Our analysis indicated that six ICD codes were 261 significantly [FDR<0.05] associated with CF [E840 and 848]; of these, pulmonary phenotypes 262 [J47, B441, J998, and J440] were significantly enriched in these participants (Fig. 5B). In an 263 attempt to characterize the clinical relevance of high impact variants, we then explored the 264 phenotypes of participants with one CF-causing variant and a high impact variant not known to 265 cause CF (n=272). Surprisingly, the only significant association [FDR<0.05] returned was 266 Melanoma in situ of the trunk which is not a classical CF phenotype. Aspergillosis was featured 267 among the top 10 most enriched phenotypes, but this association failed to meet our significance 268 threshold (Table S9). Further analysis deployed to compare differences of spirometry measures 269 (FEV1 and FVC) between participant with two CF-causing variants and the general population 270 returned no significant results.

271

#### 272 Chronological age of CF-causing variants

273

GEVA reported the estimated age of over 4,000 variants within the *CFTR* gene locus (Table S10). Only four of the dated variants were CF-causing [rs139729994 (3600G>A), rs193922500

(V456A), rs76713772 (1717-1G>A), rs77646904 (V520F)] (Fig. S1). The youngest variant 276 277 among these, 1717-1G->A, appears to have originated ~425 generations ago (~10,600 years) 278 while the earliest variant, V456A, originated about ~215 generations ago (~5,300 years). 279 Interestingly, V520F and 3600G>A which appeared ~338 and 270 generations ago featured 280 among the most common CF-causing variants reported in EAS population (Fig. 3). When the 281 allele frequencies of the CF-causing variants were compared with variants of similar ages within 282 the respective populations in AVA, there were no significant differences. Thus, an indication that 283 the variants were not under any selective pressure at the time of origination.

284

#### 285 **Discussion**

286

287 Molecular diagnosis of CF is confounded by sparse knowledge about the prevalence of 288 pathogenic and non-pathogenic CFTR variants across ancestries, including those that are 289 potentially ancestry specific. In this study, we interrogated whole-exome sequence datasets 290 generated from over 450, 000 UKBB participants to characterize the distribution of CFTR 291 variants across six ancestries [AFR, CSA, EAS, EUR, AMR, and MID], including an 292 uncharacterized group (MIX). We report, for the first time, the detection of over 4000 CFTR 293 variants across the ancestries. Among the detected ancestry-specific variants were several 294 variants of clinical and functional relevance. Phenotypic characterization of participants 295 harboring multiple combinations of these variants reported indications associated with CF and its 296 classical pulmonary phenotypes.

297

Although previous efforts driven by the CFTR1/2 team have led to the identification of just over 298 2000 CFTR variants within the CF population<sup>10</sup>, our report of over 4000 CFTR variants is a 299 300 small fraction of potential variants that could exist within the CFTR gene. In silico analyses of external variant browsers such as BRAVO<sup>17</sup>, which is based on ~132k WGS generated by the 301 TOPMed consortium, and All of Us Research Hub<sup>25</sup>, which is based on ~98k WGS and ~165k 302 303 genotyping arrays reports a total of 56,448 and 39,797 CFTR variants, respectively. The higher 304 number of CFTR variants captured in these databases are perhaps due to WGS having the 305 capability of capturing the entire length of the CFTR gene while WES captures mostly exonic 306 regions. Overall, the vast majority of the CFTR variants found in UKBB [52%], All of Us 307 Research Hub [89%], and BRAVO [96%], were intronic variants. Overall, c.1408G>A (V470M 308 [rs213950]) was the most common allele (Table S1). Although in GRCH37/38 the reference 309 allele is a G, the variation associated with increased risk of chronic pancreatitis indicate at this position is c.1408A>G (M470V)<sup>26</sup>. Regardless, a combination of this variant with another CF-310 causing does not cause CF (https://cftr2.org). CF genetic diagnosis is largely based on 311 characterized CFTR variants, most of which are reported in Europeans<sup>4,10</sup>. Although the UKBB 312 313 is dominated by people of European ancestry, which could potentially influence estimates of 314 genetic variations<sup>27</sup>, CF is one of the most common life-threatening genetic disease reported in this population<sup>28</sup>. In line, with previous reports we also found the highest number of CFTR315 316 variants in EUR population. Thus, the mutation rate of the CFTR gene is likely higher in the 317 EUR than other populations. The aspect of precision medicine for CFTR modulators is bound to 318 make higher impact in this CF population with such variable numbers of mutations.

319

Many clinically (CF-causing and VCC) and functionally (High-Impact) relevant variants were identified following cross-ancestry annotation of all detected variants. As their global

322 distribution and frequencies are poorly understood, we characterized the most common and unique CF-causing variants across populations. Indeed, like previous reports<sup>13,29,30</sup>, F508del was 323 the most common CF-causing variant reported globally. While F508del represented ~90% of the 324 325 CF-causing variants found in EUR, our findings indicate its prevalence is much lower in other 326 populations (Fig. 3). Thus, F508del may be the major cause of CF in EUR population, but not for 327 people of all ancestries. Lower frequencies of F508del in non-European populations have been 328 reported in several studies, and the spectrum of variants causing CF in such populations varies<sup>31,32</sup>. For example, G970D has been reported as the most common cause of CF in the 329 330 Chinese population<sup>12</sup>. This variant, along with V520F and 3600G>A, featured among the top 331 three common variants we found in the EAS group and were more common than F508del (Fig. 332 3). Although we found V520F to be the most common in EAS, it is conceivable G970D is more 333 common to China than V520F since the EAS group examined in this study expands beyond the 334 Chinese population. Like other non-EUR populations, CF is less frequent or likely underreported 335 in Africans<sup>10</sup>. Although F508del was the most common CF-causing variant found in the AFR group, 3120+1G>A which is predominantly found in Africans<sup>10</sup>, was also found to be common 336 337 to the AFR group (Fig. 3). Also, in South Asians, CF is thought to be less frequent. Although 338 F508del represents about 40-50% of cases, V456A the second most common CF-causing variant we found in CSA (Fig.3), is a well-characterized cause of CF in South Asians<sup>33,34</sup>. Some other 339 340 common variants found in non-EUR populations, such as AFR (3791delC), CSA (1525-1G>A), and EAS, were ancestry-specific. By comparing our findings with BRAVO reports<sup>17</sup>, we found 341 342 these variants were also rare and exclusively possessed by similar populations. Unfortunately, we 343 found most of the common CF-causing variants found in non-European populations are not 344 included in the American College of Medical Genetics list of 23 variants recommended for CF 345 carrier screening $^{35}$ .

346

347 Numerous hypotheses have been put forward to explain the persistence of CF-causing variants 348 across populations, despite their detrimental impact in life outcomes. A leading hypothesis 349 postulates the heterozygous advantage of CF-causing variants against infectious diseases, such as cholera, typhoid fever, or tuberculosis<sup>36</sup>. For example, the most common CF-causing variant, 350 rs113993960 (F508del), has been estimated to have arisen approximately 600 generations 351  $ago^{37,38}$  and its rapid increase in Europeans (MAF = 1.6%) was linked to the tuberculosis 352 353 pandemic of the seventeenth century, against which it is thought to increase resistance in mutation carriers<sup>36</sup>. Among other variants with estimated age data in AVA, we did not detect any 354 355 variant that has rapidly increased in allele frequency as the F508del variant in Europeans. 356 Although, V520F and 3600G>A are more common CF-causing variants in EAS population than 357 F508del (Fig. 3), their allele frequencies were not significantly different from other variants of 358 similar ages in EAS population. Thus, F508del is likely a unique variant that confers selective 359 pressure, which has kept its frequency relatively high.

360

Beyond CF-causing variants, we also found several VCCs, and High Impact variants not known to cause CF but predicted to severely impact protein function. R117H the common VCC, which results in reduced single-channel activity and open probability<sup>39</sup>, was the most prevalent VCC detected across the ancestries (Table S5). Clinical manifestations of patients with R117H are heterogenous and largely influenced by its combination with another CF-causing variant or other common variants of poly-T tract (5T, 7T, and 9T). R117H-T5 is reported to potentially result in less functional CFTR and pancreatic sufficiency when patients are homozygous for this

368 combination or when found in compound heterozygosity with a CF-causing variant<sup>40</sup>. Most of
369 the predicted High Impact variants found in our study were already known to cause CF (deduced
370 with the CFTR2 annotation). After excluding these variants, we still found some uncharacterized
371 High Impact variants. Taken together, these findings indicated a handful of UKBB participants
372 harbored clinically and functionally relevant *CFTR* variants.

373

374 Since CF is an autosomal recessive disease, we characterized UKBB participants with more than 375 one clinical or functional relevant variant. Interestingly, we found sixteen UKBB participants 376 with at least two CF-causing variants. Collectively, these participants reported ICD codes 377 associated with classical CF phenotypes [Fig. 5A], despite the fact only two participants 378 (F508del homozygotes) were diagnosed as CF in UKBB electronic health records. Undiagnosed 379 cases of CF, especially in patients with milder forms of the disease caused by rare pathogenic genotypes, is not uncommon<sup>41</sup>. Most of the variant combinations reported in our findings likely 380 381 result in pancreatic sufficiency, except for one participant harboring the F508del/R851X 382 genotype that results in pancreatic insufficiency. Although the F508del/R851X participant was 383 not diagnosed as CF in UKBB, the retrieved ICD10 code indicated the participant suffered 384 majorly from Chest Pain [R074]. This variant combination, which was detected in an EUR 385 participant, is less common in CF, with a frequency of only ~0.0002 recorded in CFTR2 database [https://cftr2.org]. Another rarer genotype with ~0.00002 frequency in CFTR2 which 386 we found was V456A/V456A. This variant is known to cause CF in South Asians<sup>33</sup> and likewise 387 was detected in a CSA participant. Some of the detected pathogenic genotypes, such as 388 389 L206W/S945L and R1066H/1154insTC, have not yet been recorded in CFTR2. Taken together, 390 a possible explanation for the undiagnosed cases captured in our study may be due to the 391 rareness of the variants and milder presentation of the disease.

392

393 We recorded about 10-fold more participants harboring a CF-causing variant and a VCC, than 394 those with two CF-causing variants (154 vs 16, respectively). VCCs contribute majorly to the 395 complexities associated with genetic diagnosis of CF, because clinical outcomes vary widely across patient populations<sup>42</sup>. For this sub-group of participants, we also found significant 396 397 enrichment of ICD codes associated with classical CF (ICD Codes: E840 and E848) and 398 pulmonary phenotypes, including bronchiectasis, Aspergillosis, and COPD with acute lower 399 respiratory infections. Participants with these genotypes were reported only in EUR and MIX populations, and the most dominant combination was F508del/R117H. This variant combination 400 401 on its own does not cause CF but when in *cis* with 5T ploy-Tract variant, then CF diagnosis is likely<sup>40</sup>. About 1,310 patients have the F508del/R117H variant combination in CFTR2 and 22% 402 403 of these are pancreatic insufficient. Meanwhile, 80 patients have the F508del/R117H;5T 404 combination and 33% of them are pancreatic insufficient [https://cftr2.org]. Although these 405 participants are not diagnosed as CF, their inclusion as patients in CFTR2 suggest they suffer the 406 burden of dysfunctional CFTR. The F508del/L967S genotype, which was the second most 407 common found in this subgroup (CF-causing+VCC), was rare in CFTR2. Only seven patients 408 had this combo and clinical outcome, though variable, is largely expected to be pancreatic 409 sufficient. The identification of several UKBB participants harboring such variant combinations 410 and showing CF-like symptoms, is therefore an indication that a number of undiagnosed or 411 unreported CF cases may benefit from modulator therapies. Additionally, we found no differences in pulmonary measures (FEV and FVC) between participants with two CF-causing 412 variants and the general population. Given that the UKBB recruited individuals that were over 40 413

414 years old, the individuals with multiple clinically relevant *CFTR* genotypes likely have a milder

- 415 form of the disease with a different disease etiology that nevertheless could be potentially either 416 treated or prevented by appropriate CFTR-based interventions.
- 417

418 A major drawback to existing knowledge about pathogenic CFTR variants is that most studies 419 have been conducted in European populations. However, CF is also prevalent in people from 420 other ancestries, who may harbor uncharacterized unique variants<sup>4</sup>. Even in individuals of 421 European ancestry, where most of the studies have been conducted, there are several CFTR 422 variants with unknown clinical significance. In attempt to decipher the clinical relevance of 423 uncharacterized high impact CFTR variants detected across the UKBB population, we performed 424 a phenotype analysis of participants with a CF-causing variant and a non-CF-causing 425 (uncharacterized) high impact variant but found no interesting association. Databases such as the 426 UKBB offer an unprecedented opportunity to correlate uncharacterized genotype and phenotype 427 information at a population scale. Although we utilized the UKBB resource to characterize the 428 ancestral diversity of CFTR variants, most of the participants are of European ancestry. Recent 429 genome sequencing efforts that included more diverse populations, such as the NIH All of Us 430 and ToPMed programs, report even more CFTR variants in comparison to UKBB. However, 431 limited access to phenotype information at an individual level makes it challenging to unravel the 432 clinical relevance of the detected CFTR variants.

433

434 Here, we aimed to characterize the natural variation that exists within the CFTR gene that is not 435 limited to persons with CF. The large majority (>95%) of variants surveyed have allele 436 frequencies less than 1% and  $\sim 9\%$  of all variations are indels. While sequencing technology has 437 improved in accuracy and quality control filters have removed many of the problematic variants, 438 identification, and interpretation of novel rare variants (specifically singletons and doubletons) 439 would warrant more precise methods (such as targeted sequencing) for confirmation. Another 440 limitation of our study is the lack of precise CF-related phenotypes, such as FEV1% predicted 441 and sweat chloride levels in the electronic health records extracted from UKBB. Although we 442 captured some spirometry measures, we lacked information relevant to deduce FEV1% scores 443 and there were no records of sweat chloride levels for the participants.

444

445 In summary, we have leveraged the UKBB resource to comprehensively characterize the broad 446 spectrum of CFTR variants across ancestries. Until now, most efforts aimed at identifying and 447 characterizing CFTR variants have focused more on surveying CF populations in a relatively 448 smaller sample size. For the first time, we report the detection of over 4000 CFTR variants, 449 which nearly doubles the number of variants reported by CFTR1/2. However, the higher number 450 of variants reported by the NIH All of Us and ToPMed diverse sequencing programs suggests 451 the 4000 CFTR variants represents only a small fraction of variants that exist in the CFTR gene. 452 The identification of several ancestry-specific variants, including uncharacterized functionally 453 relevant variants, warrants the need for CF screening panels to consider ethnic specificities. The presentation of classical CF phenotypes seen in some non-CF diagnosed participants, with CF-454 causing and VCC variants, indicates they may benefit from current CFTR therapies. As more 455 diverse CFTR sequences are becoming increasingly available in genomic databases, future 456 457 studies are encouraged to leverage such resources to characterize the clinical relevance of high 458 impact variants not previously known to cause CF.

#### 460 **Supplementary information**

461

Supplementary Tables 1-7: Table S1. Detected *CFTR* variants across UKBB populations; Table
S2. Unique CF-causing variants; Table S3. CF-causing *CFTR* variants; Table S4. Variable
clinical consequence variants detected across UKBB ancestries; Table S5. Unique CF-causing
variants; Table S6. Common varying clinical consequences (VCC) variants; Table S7. *CFTR*variants annotated as having High Impact; Table S8. Uncharacterized high impact variants;
Table S9. High impact and CF-Causing variants. Table S10. Dated variants within the CFTR
gene locus

- Supplementary Figures: Figure S1. Venn diagram showing genealogical estimation of variant
   age (GEVA) analysis of CF-causing variants
- 471

#### 472 Data availability

- 473
- 474 Access to UK biobank resource is available by application (http://www.ukbiobank.ac.uk/). The
- 475 UK biobank exome sequences analyzed in this study were obtained under application 26401.
- 476

# 477 Ethics declarations

478

Competing interests: The authors declare no competing interest. The design, study conduct, and
financial support for this research were provided by AbbVie. AbbVie participated in the
interpretation of data, review, and approval of the publication. JEI, ML, BRG, SRP, FR, PK, RT,
PD, AS, JFW, and AV are employees of AbbVie. HL is an employee of University of Wisconsin
School of Medicine and Public Health and provided her expertise on CF genetics and
translational research (no funding to disclose).

- 485486 Acknowledgement
- 487

488 We would like to acknowledge and extend our gratitude to the AbbVie GRC Internal Reviewers;

- 489 Anneke Den Hollander and Nizar Smaoui.
- 490

# 491 **References**

- 492
- Raraigh, K.S. *et al.* Complete CFTR gene sequencing in 5,058 individuals with cystic fibrosis informs variant-specific treatment. *J Cyst Fibros* 21, 463-470 (2022).
- 495 2. Despotes, K.A. & Donaldson, S.H. Current state of CFTR modulators for treatment of
  496 Cystic Fibrosis. *Curr Opin Pharmacol* 65, 102239 (2022).
- 497 3. Griese, M. *et al.* Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for 24 Weeks or
  498 Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results
  499 of an Open-Label Phase 3 Clinical Trial. *Am J Respir Crit Care Med* 203, 381-385
  500 (2021).

- 501 4. Guo, J., Garratt, A. & Hill, A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. *J Cyst Fibros* 21, 456-462 (2022).
- 503 5. Corvol, H. *et al.* Genome-wide association meta-analysis identifies five modifier loci of
  504 lung disease severity in cystic fibrosis. *Nat Commun* 6, 8382 (2015).
- 505 6. Petrova, N. *et al.* Ethnic Differences in the Frequency of CFTR Gene Mutations in
  506 Populations of the European and North Caucasian Part of the Russian Federation. *Front*507 *Genet* 12, 678374 (2021).
- 508 7. Schrijver, I. *et al.* The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients:
  509 Implications for Molecular Diagnostic Testing. *J Mol Diagn* 18, 39-50 (2016).
- 8. Palomaki, G.E., FitzSimmons, S.C. & Haddow, J.E. Clinical sensitivity of prenatal
  screening for cystic fibrosis via CFTR carrier testing in a United States panethnic
  population. *Genet Med* 6, 405-14 (2004).
- 513 9. Shteinberg, M., Haq, I.J., Polineni, D. & Davies, J.C. Cystic fibrosis. *Lancet* 397, 2195514 2211 (2021).
- 515 10. Stewart, C. & Pepper, M.S. Cystic Fibrosis in the African Diaspora. *Ann Am Thorac Soc*516 14, 1-7 (2017).
- 517 11. Quint, A., Lerer, I., Sagi, M. & Abeliovich, D. Mutation spectrum in Jewish cystic
  518 fibrosis patients in Israel: implication to carrier screening. *Am J Med Genet A* 136, 246-8
  519 (2005).
- 520 12. Tian, X. *et al.* p.G970D is the most frequent CFTR mutation in Chinese patients with
  521 cystic fibrosis. *Human Genome Variation* 3, 15063 (2016).
- 522 13. Ni, Q. *et al.* Systematic estimation of cystic fibrosis prevalence in Chinese and genetic
  523 spectrum comparison to Caucasians. *Orphanet J Rare Dis* 17, 129 (2022).
- Levy, H. *et al.* Identification of molecular signatures of cystic fibrosis disease status with
  plasma-based functional genomics. *Physiol Genomics* 51, 27-41 (2019).
- 526 15. Grosse, S.D. *et al.* Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. *MMWR Recomm Rep* 53, 1-36 (2004).
- 529 16. Coverstone, A.M. & Ferkol, T.W. Early Diagnosis and Intervention in Cystic Fibrosis:
  530 Imagining the Unimaginable. *Front Pediatr* 8, 608821 (2020).
- Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed
  Program. *Nature* 590, 290-299 (2021).
- Moisan, S. *et al.* Analysis of long-range interactions in primary human cells identifies
  cooperative CFTR regulatory elements. *Nucleic Acids Research* 44, 2564-2576 (2015).
- 535 19. Backman, J.D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank
  536 participants. *Nature* 599, 628-634 (2021).
- 537 20. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol 17, 122 (2016).
- 538 21. Cingolani, P. *et al.* A program for annotating and predicting the effects of single
  539 nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster
  540 strain w1118; iso-2; iso-3. *Fly (Austin)* 6, 80-92 (2012).
- 541 22. Ideozu, J.E. *et al.* Increased Expression of Plasma-Induced ABCC1 mRNA in Cystic
  542 Fibrosis. *Int J Mol Sci* 18(2017).
- 543 23. McKay, I.R. & Ooi, C.Y. The Exocrine Pancreas in Cystic Fibrosis in the Era of CFTR
  544 Modulation: A Mini Review. *Front Pediatr* 10, 914790 (2022).
- 545 24. Albers, P.K. & McVean, G. Dating genomic variants and shared ancestry in population546 scale sequencing data. *PLoS Biol* 18, e3000586 (2020).

547 25. Denny, J.C. et al. The "All of Us" Research Program. N Engl J Med 381, 668-676 (2019).

- 548 26. Zhou, D., Bai, R. & Wang, L. The Cystic Fibrosis Transmembrane Conductance
  549 Regulator 470 Met Allele Is Associated with an Increased Risk of Chronic Pancreatitis in
  550 Both Asian and Caucasian Populations: A Meta-Analysis. *Genetic Testing and Molecular*551 *Biomarkers* 24, 24-32 (2020).
- Sun, Q. *et al.* Analyses of biomarker traits in diverse UK biobank participants identify
  associations missed by European-centric analysis strategies. *J Hum Genet* 67, 87-93
  (2022).
- Blanchard, A.C. & Waters, V.J. Opportunistic pathogens in cystic fibrosis: epidemiology
  and pathogenesis of lung infection. *Journal of the Pediatric Infectious Diseases Society*11, S3-S12 (2022).
- Lima, E.d.S., Pezzin, L.S., Fensterseifer, A.C. & Pinto, L.A. Frequency of CFTR variants
  in southern Brazil and indication for modulators therapy in patients with cystic fibrosis. *Genetics and Molecular Biology* 45(2021).
- 30. Erdoğan, M. *et al.* The Genetic Analysis of Cystic Fibrosis Patients with Seven Novel
  Mutations in the CFTR Gene in the Central Anatolian Region of Turkey. *Balkan Medical Journal* 38, 357 (2021).
- Set 31. Ortiz, S.C. *et al.* Spectrum of CFTR gene mutations in Ecuadorian cystic fibrosis patients: the second report of the p.H609R mutation. *Mol Genet Genomic Med* 5, 751-757 (2017).
- 567 32. Siryani, I. *et al.* Distribution of Cystic Fibrosis Transmembrane Conductance Regulator
  568 (CFTR) Mutations in a Cohort of Patients Residing in Palestine. *PLoS One* 10, e0133890
  569 (2015).
- 570 33. Uppaluri, L., England, S.J. & Scanlin, T.F. Clinical evidence that V456A is a Cystic
  571 Fibrosis causing mutation in South Asians. *J Cyst Fibros* 11, 312-5 (2012).
- 572 34. Indika, N.L.R. *et al.* Phenotypic spectrum and genetic heterogeneity of cystic fibrosis in
  573 Sri Lanka. *BMC Medical Genetics* 20, 89 (2019).
- 574 35. Deignan, J.L. *et al.* CFTR variant testing: a technical standard of the American College of
  575 Medical Genetics and Genomics (ACMG). *Genetics in Medicine* 22, 1288-1295 (2020).
- 576 36. Poolman, E.M. & Galvani, A.P. Evaluating candidate agents of selective pressure for cystic fibrosis. *J R Soc Interface* 4, 91-8 (2007).
- Morris, A.P., Whittaker, J.C. & Balding, D.J. Fine-scale mapping of disease loci via shattered coalescent modeling of genealogies. *Am J Hum Genet* **70**, 686-707 (2002).
- Slatkin, M. & Bertorelle, G. The use of intraallelic variability for testing neutrality and estimating population growth rate. *Genetics* 158, 865-74 (2001).
- S82 39. Yu, Y.C., Sohma, Y. & Hwang, T.C. On the mechanism of gating defects caused by the
  R117H mutation in cystic fibrosis transmembrane conductance regulator. *J Physiol* 594,
  S227-44 (2016).
- 585 40. Castellani, C. *et al.* Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. *J Cyst Fibros* 7, 179-96 (2008).
- 587 41. Sagesse, G.J., Yadava, S. & Mandava, A. Atypical Cystic Fibrosis: Diagnosis at the Age
  588 of 57 Years. *Cureus* 12, e10863 (2020).
- 589 42. De Wachter, E., Thomas, M., Wanyama, S.S., Seneca, S. & Malfroot, A. What can the
  590 CF registry tell us about rare CFTR-mutations? A Belgian study. *Orphanet Journal of*591 *Rare Diseases* 12, 142 (2017).
- 592

#### 

Approximate global ancestry	Sample Size, n (%)	Gender: Male, n (%)	Age in Years, Median (IQR)	<i>CFTR</i> Variants, n (%)	Unique <i>CFTR</i> Variants, n (%)
African (AFR)	6278 (1.4%)	2582 (41%)	62 (57,70)	417 (9.9%)	138 (33.1%)
Central South Asia (CSA)	8470 (1.9%)	4572 (54%)	65 (58, 72)	471 (11.2%)	177 (37.6%)
East Asia (EAS)	2608 (0.6%)	886 (34%)	63 (57,70)	266 (6.3%)	104 (39.1%)
European (EUR)	397,073 (87.3%)	182164 (46%)	70 (62,75)	3192 (76.1%)	2212 (69.3%)
American/Admixed American (AMR)	950(0.2%)	334 (35%)	63 (57,71)	151 (3.6%)	23 (15.2%)
Middle East (MID)	1498 (0.3%)	872 (58%)	63 (57,70)	222 (5.3%)	46 (20.7%)
MIX	37850(8.3%)	16450 (43%)	67 (60,67)	1333 (31.8%)	381 (28.6%)

#### Table 1. Diversity of CFTR variants across ancestries

#### Table 2. Number of participants with CF-causing variants across ancestries

Ancestries	Sample Size in UKBB	<i>CFTR</i> Variants	CF- Causing	Varying Clinical Consequences (VCC)	High Impact Variants
AFR	6278	417	22	12	16
AMR	950	151	7	10	4
CSA	8470	471	17	6	15
EAS	2608	266	8	6	4
EUR	397,073	3,192	116	29	150
MID	1498	222	8	12	7
MIX	37850	1,333	85	29	70

#### Table 3. Participants with two CF-causing variants

Ancestry	Variant1	Variant2	Number of Variant	Predicted Phenotype	CFTR2 Participants* [n]
EUR	L206W	R553X	1	Pancreatic Sufficient	3
	L206W	S945L	1	Pancreatic Sufficient	0
	R851X	F508del	1	Pancreatic Insufficient	16
	R1066H	F508del	1	Pancreatic Sufficient	56
	R1066H	1154insTC	1	Pancreatic Sufficient	0
	P67L	G551D	1	Pancreatic Sufficient	12

	P67L	F508del	1	Pancreatic Sufficient	186
	711+3A->G	F508del	1	Pancreatic Sufficient	42
	F508del	F508del	1	Pancreatic Insufficient	33984
міх	F508del	D110H	2	Pancreatic Sufficient	34
	F508del	L206W	1	Pancreatic Sufficient	235
	F508del	F508del	1	Pancreatic Insufficient	33984
	3600G->A	F508del	1	Pancreatic Sufficient	15
	E474K	F508del	1	Pancreatic Sufficient	3
<b>C</b> SV	V456A	V456A	1	Pancreatic Sufficient	2

Ancestry	Variant1	Variant2	Count
EUR	R117H	F5 08del	38
_	L967 S	F5 08del	30
_	D443Y	F5 08del	13
_	P750L	F5 08de	12
_	621+3A->G	F508de	5
_	R334Q	F508del	4
_	P750L	G551D	3
=	R258G	F5 08del	3
=	D1152H	F508del	2
-	F1052V	F508del	2
=	L967S	1717-1G->A	2
=	L967S	G551D	2
-	L967 S	W1282X	2
-	Q1291H	F5 08de	2
-	R1070W	F5 08de	2
-	D1270N	F508de	1
-	D443Y	1898+1G->A	1
-	D443Y	N1303K	1
	D443Y	Q493X	1
	D443Y	R553X	1
-	F575Y	1154insTC	1
	L967S	1138insG	1
	L967S	1898+1G->A	1
-	L967S	3659delC	1
	M265 R	F508de	1
-	P750L	1461ins4	1
	P750L	R560T	1
-	P750L	W846X	1
-	R1070Q	F508de	1
=	R1070W	G542X	1
=	R117G	F5 08del	1
=	R117H	1898+1G->A	1
-	R117H	2184delA	1
-	R117H	3272-26A->G	1
=	R117H	1507del	1

	R117H	R347P	1
	R352W	N1303K	1
MIX	R117H	F5 08del	5
	621+3A->G	F5 08del	1
	D443Y	F5 08del	1
	D1152H	1898+1G->A	1
	F1052V	F5 08del	1
	Q1476X	N1303K	1

612

#### Fig. 1: Most CFTR variants are intronic



#### Variant types and consequences

Several variant types with varying consequences were identified in the *CFTR* gene. The labels in the chart represent the number and percentage of the Intronic variants (highlighted in orange) clearly dominated over half of the captured variants despite Whole Exome Sequencing technology capturing mostly exomes.

#### Fig. 2: Ancestry-specific variants characterized



#### Intersection of CFTR variants across ancestries

**A)** Graph of total number of variants (x-axis; Set Size) detected in each ancestry (y-axis). **B)** Intersection of variants detected across the ancestries. Each column corresponds to the number of variants in each intersection. Ancestries present in each intersection are represented by the black dots. Intersections with single dots represents ancestry-specific variants. **C)** A list of ancestry-specific variants. The highest number of unique *CFTR* variants (2212/3192) was detected in Europeans.

# Fig. 3: Common CF-causing variants in each ancestry represented in pie charts

**Common CF-causing variants across ancestries** 



For each ancestry, slices vary by color, with blue representing the most abundant CF-causing variant. F508del was the most common CF-causing variant detected in all ancestries, except for East Asia where V520F was the most common.

#### Fig. 4: Ancestry-specific CF-causing variants characterized



Intersection of CF-causing variants across ancestries

A) Graph of total number of variants (x-axis; Set Size) detected in each ancestry (y-axis). B) Intersection of variants detected across the ancestries. Each column corresponds to the number of variants in each intersection. Ancestries present in each intersection are represented by the black dots. Intersections with single dots represents ancestry-specific CF-causing variants. C) A list of ancestry-specific CF-causing variants. The highest number of unique CF-causing variants (n=50) was detected in Europeans.

Fig. 5: Classical CF phenotypes enriched in participants with >1 clinically relevant *CFTR* variant



A) Enriched phenotypes observed in patients with two CF-causing variants B) Enriched phenotypes observed in patients with one CF-causing and a high impact variant. The top 10 enriched phenotypes are represented in bar graphs. The negative logarithm of the Bonferroni adjusted p-value was used to deduce the enrichment scores shown in the bars. Enrichment score >1.3 corresponds to a significance threshold of p<0.05.